BioNTech SE (BNTX) Stock News: October 2026

$BNTX · 1 story in October 2026

October 2026

newest first · direct subject stories only

Corporatedeveloping · 3 wiresOct 13 · 6:54 AM ET

BioNTech BNT113 trial misses PFS endpoint, continues for overall survival

BioNTech's Phase 2/3 trial for BNT113 plus pembrolizumab missed the PFS endpoint in HPV16+ head and neck cancer. The trial continues for the OS endpoint, which could still yield a positive outcome.

bearish 30 · impact 60

BioNTech BNT113 clinical trial update: a laboratory flask remains intact on a stone base as one path ends while another continues upward.